We have just released the latest update to the Open Targets Platform — 26.03.
Key stats
| Metric | Count |
|---|---|
| Targets | 78,691 |
| Diseases/phenotypes | 47,030 |
| Drugs/Clinical candidates | 22,230 |
| Variants | 7,432,549 |
| Evidence | 34,086,838 |
| Associations | 12,466,856 |
Number of credible sets
| Metric | Count |
|---|---|
| GWAS | 1,446,959 |
| eQTL | 1,349,418 |
| tuQTL | 384,849 |
| sQTL | 223,500 |
| sceQTL | 52,738 |
| pQTL | 33,718 |
Number of unique studies in GWAS credible sets: 52,219
Number of unique biosampleIDs (number of tissues/cell types) from molQTLs: 98
Evidence metrics for this release
- 4,035,263 genetic evidence from European Variation Archive (EVA)
- 3,029,759 GWAS credible sets from GWAS Catalog, FinnGen through Gentropy
- 5,026 genetic evidence from Gene2Phenotype
- 46,905 genetic evidence from the Genomics England PanelApp
- 3,894 genetic evidence from ClinGen
- 7,245 genetic evidence from Orphanet
- 40,444 genetic evidence from Open Targets’ Gene burden integration
- 21,659 genetic evidence from CRISPRBrain
- 6,682 genetic evidence from UniProt Literature
- 9,366 somatic evidence from European Variation Archive (EVA)
- 4,223 somatic evidence from intOGen
- 91,572 somatic evidence from the Cancer Gene Census
- 36,814 somatic evidence from Uniprot
- 599,344 clinical precedence evidence from the Open Targets Clinical Mining pipeline
- 237,329 expression evidence from Expression Atlas
- 10,748 affected pathway evidence from Reactome
- 1,301 affected pathway evidence from the [Cancer Genome Interpreter] (Cancer Biomarkers) (Cancer Genome Interpreter - Identification of therapeutically actionable genomic alterations in tumors)
- 517 CRISPR-Cas9 (Cancer Cell Lines) evidence from Pacini et al. (2024)
- 1,522,457 mouse model evidence from IMPC
- 24,376,290 scientific literature evidence from co-occurrence mining in Europe PMC
For more details and numbers, read the 26.03 blog post.